Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK/XenoPort Next-Generation RLS Drug Shows Efficacy In Phase III

This article was originally published in The Pink Sheet Daily

Executive Summary

NDA filing for the non-dopaminergic candidate is on track for third quarter.

You may also be interested in...



FDA Wants Solzira Restless Legs Data Reformatted

Filing’s content is unaffected, says GlaxoSmithKline, which withdrew the recently submitted NDA but will resubmit it “as quickly as possible.”

FDA Wants Solzira Restless Legs Data Reformatted

Filing’s content is unaffected, says GlaxoSmithKline, which withdrew the recently submitted NDA but will resubmit it “as quickly as possible.”

GSK, XenoPort Will Include Two-Dose Data In NDA For Restless Legs Drug

Positive efficacy with 600 mg a "surprise," XenoPort CEO says.

Related Content

Topics

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel